Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KEAP1 mut STK11 mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KEAP1 mut STK11 mut | lung adenocarcinoma | not predictive | unspecified PD-1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring both a KEAP1 mutation and STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 and wild-type STK11 when treated with an unspecified PD-1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 | |
| KEAP1 mut STK11 mut | lung adenocarcinoma | not predictive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring both a KEAP1 mutation and STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 and wild-type STK11 when treated with an unspecified PD-L1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |